Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

“The data presented today confirm nivolumab plus ipilimumab as a new standard treatment for people ... the first immune-oncology combination approved by the FDA for metastatic melanoma. The ...

HCC in the Rio Grande Valley: Outcomes in a predominant Latino community. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full ...

Concurrent transarterial chemoembolization plus atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: Interim analysis from a multicenter real-world study (CHANCE 023). This is an ...

First-line nivolumab plus ipilimumab was shown to be effective and well-tolerated in patients with unresectable hepatocellular carcinoma in the CheckMate 9DW study. In patients with unresectable ...